Sacral neuromodulation for fecal incontinence and “low anterior resection syndrome” following neoadjuvant therapy for rectal cancer
Author:
- 5 April 2013
- journal article
- clinical trial
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 28 (5) , 665-669
Abstract
It was the aim of this prospective study to analyze both feasibility and effectiveness of sacral neuromodulation for fecal incontinence and “low anterior resection syndrome” following neoadjuvant therapy for rectal cancer. All patients who underwent sacral neuromdulation following neoadjuvant therapy for rectal cancer (preoperative radiochemotherapy, oncologic rectal resection with total mesorectal excision) were prospectively enrolled in the study. Only patients with failure of conservative treatment and without any evidence of residual or recurrent tumor disease were candidates for sacral neuromdulation which was performed by a two-stage procedure (diagnostic percutaneous test stimulation followed by definite implant). In addition to feasibility, primary end points included success (reduction of incontinent episodes), continence and defecation status (assessed by Cleveland Clinic Incontinence Score and Altomare score), and quality of life (EQ-5D). Anal manometry was performed preoperative and at 12-month follow-up. Follow-up information was derived from clinical examination 3, 6, and 12 months postoperatively. Nine patients (three females, six males) with a mean age of 61 years underwent sacral neuromodulation following neoadjuvant therapy for rectal cancer. Implantation rate was 100 %. No septic morbidity was observed. After a mean follow-up of 12 months, mean Cleveland Clinic Incontinence Score was reduced from 18.2 to 6.0 (p < 0.01). Incontinence episodes were significantly reduced from 7 to 0.5 (per day) and 20 to 8 (per week). Fecal urgency, fragmented defecation, and soiling were improved or resolved in two thirds. Altomare score was significantly reduced from 21.0 to 9.3 (p < 0.01). Anorectal manometry did not correlate with clinical success. Quality of life was significantly improved (EQ-5D generic: 0.42 vs. 0.74, EQ-5D-VAS score: 20 vs. 90, p < 0.01). Preliminary results of sacral neuromodulation in patients with fecal incontinence and symptoms of “low anterior resection syndrome” are promising and enrich the therapeutic modalities if conservative management has failed.Keywords
This publication has 32 references indexed in Scilit:
- Stellenwert der konservativen Therapie bei StuhlinkontinenzZentralblatt fur Chirurgie, 2012
- A Comparative Study of Voiding and Sexual Function after Total Mesorectal Excision with Autonomic Nerve Preservation for Rectal Cancer: Laparoscopic Versus Robotic SurgeryAnnals of Surgical Oncology, 2012
- Quality of Life Is Markedly Improved in Patients With Fecal Incontinence After Sacral Nerve StimulationUrogynecology, 2012
- Functional disorders after rectal cancer resection: does a rehabilitation programme improve anal continence and quality of life?Colorectal Disease, 2012
- Management of fecal incontinence after treatment for rectal cancerCurrent Opinion in Supportive & Palliative Care, 2011
- Fecal Incontinence: Etiology, Evaluation, and TreatmentClinics in Colon and Rectal Surgery, 2011
- Risk factors for faecal incontinence after rectal cancer treatmentBritish Journal of Surgery, 2007
- Sacral Neuromodulation in Treatment of Fecal Incontinence Following Anterior Resection and Chemoradiation for Rectal CancerDiseases of the Colon & Rectum, 2005
- Bilateral sacral spinal nerve stimulation for fecal incontinence after low anterior rectum resectionInternational Journal of Colorectal Disease, 2002
- Etiology and management of fecal incontinenceDiseases of the Colon & Rectum, 1993